A process for purifying apolipoprotein a or apolipoprotein e from human plasma
CA 2274241 C · Owner: Esperion Therapeutics Inc. · Inventors: Winge, Stefan; Wiklund, Sara
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to a process for purifying apolipoprotein A (ApoA) or apolipoprotein E (ApoE) from human plasma by obtaining a fraction , of human plasma containing said ApoA or ApoE prepurifying said fraction in at , least one step binding said ApoA or ApoE to an anion-exchange chromatography gel, and thereafter eluting said ApoA or ApoE from said anion-exchange chromatography gel. The thus produced ApoA or ApoE can be used for the manufacture of a medicament in the treatment of atherosclerosis and cardiovascular diseases, or peripheral atherosclerosis and sepsis as well as in a method for treatment of atherosclerosis and cardiovascular diseases or , peripheral …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 22, 1997 and granted May 27, 2003. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended August 22, 2017.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 22, 2019.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.